Target intelligence / Profile preview

Large ribosomal subunit protein uL1 (uL1)

Target
uL1
Molecular classification
Ribosomal protein, Structural constituent of ribosome[1][5][10], Other (L1P family of ribosomal proteins)[5]
01

Overview

Large ribosomal subunit protein uL1 is a highly conserved structural component of the large 60S/50S subunit of both prokaryotic and eukaryotic ribosomes. It binds directly to 23S rRNA within the so-called "L1 stalk," which is mobile within the assembled particle. This mobility allows it to participate actively in releasing deacylated tRNAs from the E site during translation termination or translocation steps. The human version is encoded by RPL10A; alternative names include NEDD6 and CSA19 among others. While not typically considered a classical drug target outside antibacterial therapy, it can be targeted by antibiotics such as clindamycin that exploit differences between bacterial and mammalian translational machinery for selective inhibition.[1][5][9]

Other names
60S ribosomal protein L10aRPL10ANEDD6CSA19Csa-19L10Aribosomal protein L10a[5]
02

Mechanism of action

Drugs like clindamycin inhibit bacterial translation by targeting the large ribosomal subunit—specifically interfering with peptide elongation or tRNA translocation at the E site where uL1 plays a role[1].

03

Biological functions

rRNA binding[1][9]tRNA binding and release (involved in E site tRNA release)[1][9]Structural component of the large (60S) ribosomal subunit[5][8]Regulation of translation and maturation of LSU-rRNA[1]
04

Disease associations

There is no direct evidence linking this specific protein to major disease categories such as cancer, inflammation, or neurodegenerative diseases.However, its expression is downregulated by cyclosporin-A in the thymus and during neural development in mice, suggesting possible roles in immune function and neural development regulation[5].For most therapeutic contexts, it is not a primary disease driver but may be relevant for infection due to its essential role in translation.
05

Safety considerations

Targeting eukaryotic homologs could disrupt global protein synthesis leading to cytotoxicity.Inhibitors are primarily used against bacterial forms due to differences between prokaryotic and eukaryotic ribosomes.Off-target effects on mitochondrial or cytoplasmic human homologs could pose safety risks.
06

Interacting drugs

Clindamycin (approved; inhibitor)[1]

1 more in the full profile.

07

Biomarkers

No established biomarkers for patient selection or efficacy monitoring are reported for this target.

Beyond the preview

Go deeper on Large ribosomal subunit protein uL1 (uL1).

Explore the evidence, development activity, and competitive landscape with Gosset’s full data platform.

Drug pipeline

Full profile access

Explore the programs pursuing this target and their development progress.

  • Drug candidates
  • Developers
  • Development stage

Clinical trials

Full profile access

Follow the clinical studies evaluating therapies directed at this target.

  • Trial design
  • Status
  • Readouts

Competitive landscape

Full profile access

Compare approaches across drug candidates, modalities, and indications.

  • Programs
  • Modalities
  • Indications

Literature & evidence

Full profile access

Investigate the research and source evidence behind target biology and development.

  • Publications
  • Sources
  • Analysis

Patents

Full profile access

Explore patent activity around therapies and technologies addressing this target.

  • Patents
  • Assignees
  • Technologies

Research & analysis

Full profile access

Connect target biology, drug development, and emerging evidence in your research.

  • Biology
  • Development news
  • Analysis

Bring the full picture into focus.

See how Gosset can support your research on Large ribosomal subunit protein uL1 (uL1).

Explore the full profile

Gosset Free

Get started with Gosset.

Enter your work email and we’ll be in touch with next steps.

Work email preferred.

Book a call